MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target

MoonLake Immunotherapeutics is advancing a promising therapy, SLK, targeting inflammatory skin and joint diseases, with recent clinical trials showing significant improvements in patient outcomes that bolster the company's outlook. The probability of regulatory approval for SLK in treating hidradenitis suppurativa (HS) has been increased to 40%, reflecting confidence in its effectiveness and potential market impact. Additionally, the HS market is projected to grow significantly to over $10 billion annually by the mid-2030s, indicating a substantial opportunity for MoonLake to establish a competitive position and drive shareholder value.

MoonLake Immunotherapeutics exhibits several financial concerns that contribute to a negative outlook on its stock. General and administrative expenses in the third quarter of 2025 were reported at $10.8 million, slightly under the anticipated $12 million, while projected total expenses for 2025 and 2026 show only a modest decline, suggesting persistent high operational costs. Moreover, the company faces significant risks related to the advancement and efficacy of its lead therapy SLK, including potential delays in pivotal trials and regulatory submissions, which could hinder market approval and financial performance in an increasingly competitive and price-sensitive landscape.